HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ng, M K C Articles by Celermajer, D S Search for Related Content PubMed PubMed Citation Articles by Ng, M K C Articles by Celermajer, D S

Glucocorticoid treatment and cardiovascular disease

Department of Medicine, University of Sydney, Australia

Correspondence to:
Correspondence to:
Professor David S Celermajer
Department of Cardiology, Royal Prince Alfred Hospital, Camperdown, Sydney, NSW 2050, Australia; david.celermajer{at}email.cs.nsw.gov.au

ABSTRACT
The propensity of glucocorticoids to produce hyperglycaemia, hypertension, dyslipidaemia, and central obesity has long been a cause for concern among physicians regarding possible adverse cardiovascular events. Should heart failure be added to this list of concerns?

Keywords: glucocorticoids; hyperglycaemia; hypertension; dyslipidaemia; heart failure

This article has been cited by other articles:

				J. E. Goodwin, J. Zhang, and D. S. Geller A Critical Role for Vascular Smooth Muscle in Acute Glucocorticoid-Induced Hypertension J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1291 - 1299. [Abstract] [Full Text] [PDF]

				Q. M. Chen, D. Alexander, H. Sun, L. Xie, Y. Lin, J. Terrand, S. Morrissy, and S. Purdom Corticosteroids Inhibit Cell Death Induced by Doxorubicin in Cardiomyocytes: Induction of Antiapoptosis, Antioxidant, and Detoxification Genes Mol. Pharmacol., June 1, 2005; 67(6): 1861 - 1873. [Abstract] [Full Text] [PDF]